Resistance to receptor-blocking therapies primes tumors as targets for HER3-homing nanobiologics
对受体阻断疗法的耐药性使肿瘤成为 HER3 归巢纳米生物制剂的靶点
期刊:Journal of Controlled Release
影响因子:10.5
doi:10.1016/j.jconrel.2017.12.024
Jessica D Sims, Jan Michael Taguiam, Felix Alonso-Valenteen, Janet Markman, Hasmik Agadjanian, David Chu, Jay Lubow, Ravinder Abrol, Dustin Srinivas, Anjali Jain, Bingchen Han, Ying Qu, Parisa Mirzadehgan, Jae-Youn Hwang, Altan Rentsendorj, Alice Chung, Jenny Lester, Beth Y Karlan, Harry B Gray, Zee
